Melanie Baxter

2.7k total citations
76 papers, 1.6k citations indexed

About

Melanie Baxter is a scholar working on Molecular Medicine, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Melanie Baxter has authored 76 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Medicine, 39 papers in Epidemiology and 26 papers in Clinical Biochemistry. Recurrent topics in Melanie Baxter's work include Antibiotic Resistance in Bacteria (44 papers), Bacterial Identification and Susceptibility Testing (26 papers) and Antibiotics Pharmacokinetics and Efficacy (22 papers). Melanie Baxter is often cited by papers focused on Antibiotic Resistance in Bacteria (44 papers), Bacterial Identification and Susceptibility Testing (26 papers) and Antibiotics Pharmacokinetics and Efficacy (22 papers). Melanie Baxter collaborates with scholars based in Canada, Italy and United States. Melanie Baxter's co-authors include George G. Zhanel, Heather J. Adam, James A. Karlowsky, Andrew Walkty, Philippe Lagacé‐Wiens, D. J. Hoban, Kimberly A. Nichol, Daryl J. Hoban, Andrew Denisuik and Alyssa Golden and has published in prestigious journals such as Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Melanie Baxter

72 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melanie Baxter Canada 24 841 679 448 337 320 76 1.6k
Kim Nichol Canada 19 756 0.9× 674 1.0× 375 0.8× 376 1.1× 207 0.6× 33 1.5k
Kimberly A. Nichol Canada 25 713 0.8× 1.1k 1.6× 404 0.9× 480 1.4× 473 1.5× 36 1.9k
Simona Barnini Italy 25 1.1k 1.3× 641 0.9× 509 1.1× 401 1.2× 492 1.5× 59 1.9k
Michael Kresken Germany 21 669 0.8× 474 0.7× 426 1.0× 448 1.3× 310 1.0× 73 1.4k
Demei Zhu China 25 1.3k 1.5× 633 0.9× 594 1.3× 444 1.3× 359 1.1× 65 2.0k
Dee Shortridge United States 29 1.3k 1.5× 768 1.1× 800 1.8× 528 1.6× 368 1.1× 85 2.6k
S. Bouchillon United States 19 882 1.0× 623 0.9× 371 0.8× 175 0.5× 250 0.8× 34 1.4k
Iciar Rodríguez-Avial Spain 23 580 0.7× 469 0.7× 347 0.8× 435 1.3× 285 0.9× 66 1.4k
Tiziana D’Inzeo Italy 21 719 0.9× 633 0.9× 205 0.5× 421 1.2× 692 2.2× 47 1.6k
Elena Loza Spain 23 507 0.6× 783 1.2× 272 0.6× 448 1.3× 316 1.0× 61 1.6k

Countries citing papers authored by Melanie Baxter

Since Specialization
Citations

This map shows the geographic impact of Melanie Baxter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Baxter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Baxter more than expected).

Fields of papers citing papers by Melanie Baxter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Baxter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Baxter. The network helps show where Melanie Baxter may publish in the future.

Co-authorship network of co-authors of Melanie Baxter

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Baxter. A scholar is included among the top collaborators of Melanie Baxter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Baxter. Melanie Baxter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhanel, George G., Melanie Baxter, Philippe Lagacé‐Wiens, et al.. (2025). Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. 80(Supplement_2). ii15–ii26. 1 indexed citations
2.
Mataseje, Laura, Nicole Lerminiaux, Philippe Lagacé‐Wiens, et al.. (2025). Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23). Journal of Antimicrobial Chemotherapy. 80(Supplement_2). ii54–ii61. 1 indexed citations
3.
Lagacé‐Wiens, Philippe, Laura Mataseje, Melissa McCracken, et al.. (2025). Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23. Journal of Antimicrobial Chemotherapy. 80(Supplement_2). ii45–ii53. 1 indexed citations
4.
Zhanel, George G., Michael H. Silverman, Melanie Baxter, et al.. (2024). Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. Journal of Global Antimicrobial Resistance. 38. 154–157. 6 indexed citations
5.
Zhanel, George G., Melanie Baxter, Sergio Borgia, et al.. (2024). How is ceftobiprole used in Canada: the CLEAR study final results. Expert Review of Anti-infective Therapy. 22(8). 681–688. 4 indexed citations
6.
7.
Adam, Heather J., James A. Karlowsky, Melanie Baxter, et al.. (2023). Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020. Journal of Antimicrobial Chemotherapy. 78(Supplement_1). i17–i25. 8 indexed citations
8.
9.
Karlowsky, James A., Melanie Baxter, Andrew Walkty, et al.. (2022). In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study. Journal of Antimicrobial Chemotherapy. 77(11). 3035–3038. 8 indexed citations
10.
Karlowsky, James A., Andrew Walkty, Melanie Baxter, et al.. (2022). In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. Microbiology Spectrum. 10(4). e0172422–e0172422. 15 indexed citations
11.
Golden, Alyssa, Melanie Baxter, James A. Karlowsky, et al.. (2021). Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC-Antimicrobial Resistance. 4(1). dlab197–dlab197. 18 indexed citations
12.
Golden, Alyssa, James A. Karlowsky, Andrew Walkty, et al.. (2021). Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007–18. Journal of Antimicrobial Chemotherapy. 76(11). 2825–2832. 7 indexed citations
13.
Zhanel, George G., Melanie Baxter, Carlos Cervera, et al.. (2021). Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. Journal of Global Antimicrobial Resistance. 25. 346–350. 10 indexed citations
14.
Walkty, Andrew, James A. Karlowsky, Melanie Baxter, et al.. (2019). Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007–2017). Diagnostic Microbiology and Infectious Disease. 96(3). 114962–114962. 3 indexed citations
15.
Zhanel, George G., Melanie Baxter, Heather J. Adam, Joyce A. Sutcliffe, & James A. Karlowsky. (2017). In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diagnostic Microbiology and Infectious Disease. 91(1). 55–62. 63 indexed citations
16.
Lagacé‐Wiens, Philippe, Heather J. Adam, Nancy M. Laing, et al.. (2017). Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential. Journal of Antimicrobial Chemotherapy. 72(8). 2273–2277. 27 indexed citations
17.
Walkty, Andrew, James A. Karlowsky, Heather J. Adam, et al.. (2016). Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). CMAJ Open. 4(4). E641–E645. 25 indexed citations
18.
Karlowsky, James A., Andrew Walkty, Melanie Baxter, Heather J. Adam, & George G. Zhanel. (2014). In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013. Diagnostic Microbiology and Infectious Disease. 80(4). 311–315. 12 indexed citations
19.
Nichol, Kimberly A., Heather J. Adam, D. Roscoe, et al.. (2013). Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. Journal of Antimicrobial Chemotherapy. 68(suppl 1). i47–i55. 38 indexed citations
20.
Zhanel, George G., Heather J. Adam, Melanie Baxter, et al.. (2013). Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. Journal of Antimicrobial Chemotherapy. 68(suppl 1). i7–i22. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim Nichol Breakdown of academic impact, for papers by Kimberly A. Nichol Breakdown of academic impact, for papers by Simona Barnini Breakdown of academic impact, for papers by Michael Kresken Breakdown of academic impact, for papers by Demei Zhu Breakdown of academic impact, for papers by Dee Shortridge Breakdown of academic impact, for papers by S. Bouchillon Breakdown of academic impact, for papers by Iciar Rodríguez-Avial Breakdown of academic impact, for papers by Tiziana D’Inzeo Breakdown of academic impact, for papers by Elena Loza
Rankless by CCL
2026